| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
8,399 |
7,282 |
$812K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,188 |
5,540 |
$452K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
6,331 |
5,709 |
$324K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,115 |
2,106 |
$209K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,001 |
993 |
$152K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
1,796 |
1,724 |
$70K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
934 |
929 |
$61K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,349 |
1,150 |
$41K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,506 |
1,477 |
$26K |
| 0012A |
|
283 |
283 |
$11K |
| 0011A |
|
289 |
289 |
$11K |
| M0240 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses |
21 |
21 |
$9K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
166 |
162 |
$8K |
| 93000 |
|
83 |
80 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
44 |
44 |
$778.18 |
| 81003 |
|
513 |
492 |
$627.42 |
| 87807 |
|
45 |
43 |
$534.88 |
| 81025 |
|
29 |
28 |
$299.01 |
| 90688 |
|
13 |
12 |
$142.46 |
| 91301 |
|
605 |
596 |
$3.75 |
| Q0240 |
Injection, casirivimab and imdevimab, 600 mg |
20 |
20 |
$0.12 |